MSB 3.21% $1.13 mesoblast limited

Ruxolitinib passed FDA approval on poorer single arm study results than Ryconcil, page-2

  1. 2,101 Posts.
    lightbulb Created with Sketch. 218
    So if FDA rejected us when Ruxo....etc was approved would stand out like a sore thumb. Not saying that will happen or it’s a reason we will or won’t get approved but at face value that would be odd.

    They have their responses ready and we just have to wait.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.